Page 109 - Read Online

Link et al. Roles of p53 in extrinsic factor-induced liver carcinogenesis

8. Chuang SC, La Vecchia C, Boffetta P. Liver cancer: descriptive Nature 1991;350:429-31.
epidemiology and risk factors other than HBV and HCV infection. 28. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the
Cancer Lett 2009;286:9-14. transversion of G-->T in codon 249 of the p53 tumor suppressor
9. Magnussen A, Parsi MA. Aflatoxins, hepatocellular carcinoma and gene in human hepatocytes. Proc Natl Acad Sci U S A
public health. World J Gastroenterol 2013;19:1508-12. 1993;90:8586-90.
10. Guyton KZ, Kensler TW. Prevention of liver cancer. Curr Oncol 29. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N,
Rep 2002;4:464-70. Shao Y, Wu Z, Liu G, Wang X, Sun Z. Dominant role of hepatitis
11. Wertheim JA, Petrowsky H, Saab S, Kupiec-Weglinski JW, Busuttil B virus and cofactor role of aflatoxin in hepatocarcinogenesis in
RW. Major challenges limiting liver transplantation in the United Qidong, China. Hepatology 2002;36:1214-20.
States. Am J Transplant 2011;11:1773-84. 30. Puisieux A, Lim S, Groopman J, Ozturk M. Selective targeting of
12. Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari p53 gene mutational hotspots in human cancers by etiologically
G, Vitale A. Prediction of hepatocellular carcinoma biological defined carcinogens. Cancer Res 1991;51:6185-9.
behavior in patient selection for liver transplantation. World J 31. Hussain SP, Harris CC. p53 mutation spectrum and load: the
Gastroenterol 2016;22:232-52. generation of hypotheses linking the exposure of endogenous or
13. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, exogenous carcinogens to human cancer. Mutat Res 1999;428:23-
Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, 32.
Lewis DR, Chen HS, Feuer EJ, Cronin KA (editors). SEER Cancer 32. Ricordy R, Gensabella G, Cacci E, Augusti-Tocco G. Impairment
Statistics Review, 1975-2013. Bethesda, MD: National Cancer of cell cycle progression by aflatoxin B1 in human cell lines.
Institute. Available from: http://seer.cancer.gov/csr/1975_2013/. Mutagenesis 2002;17:241-9.
[Based on November 2015 SEER data submission; posted to the 33. Kim J, Park SH, Do KH, Kim D, Moon Y. Interference with
SEER web site on April 2016; last accessed on May 26, 2017]. mutagenic aflatoxin B1-induced checkpoints through antagonistic
14. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer action of ochratoxin A in intestinal cancer cells: a molecular
2009;9:691-700. explanation on potential risk of crosstalk between carcinogens.
15. Lane D, Levine A. p53 Research: the past thirty years and the next Oncotarget 2016;7:39627-39.
thirty years. Cold Spring Harb Perspect Biol 2010;2:a000893. 34. Lee YI, Lee S, Das GC, Park US, Park SM, Lee YI. Activation
16. Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, Tan of the insulin-like growth factor II transcription by aflatoxin B1
TX, Wu MC, Getz G, Lawrence MS, Parker JS, Li J, Powers S, Kim induced p53 mutant 249 is caused by activation of transcription
H, Fischer S, Guindi M, Ghanekar A, Chiang DY. Identification complexes; implications for a gain-of-function during the formation
of driver genes in hepatocellular carcinoma by exome sequencing. of hepatocellular carcinoma. Oncogene 2000;19:3717-26.
Hepatology 2013;58:1693-702. 35. Whittaker S, Marais R, Zhu AX. The role of signaling pathways
17. Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro in the development and treatment of hepatocellular carcinoma.
J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Oncogene 2010;29:4989-5005.
Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc 36. Weng CJ, Hsieh YH, Tsai CM, Chu YH, Ueng KC, Liu YF, Yeh YH,
JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage Su SC, Chen YC, Chen MK, Yang SF. Relationship of insulin-like
P, Stratton MR, Llovet JM, Zucman-Rossi J. Exome sequencing of growth factors system gene polymorphisms with the susceptibility
hepatocellular carcinomas identifies new mutational signatures and and pathological development of hepatocellular carcinoma. Ann
potential therapeutic targets. Nat Genet 2015;47:505-11. Surg Oncol 2010;17:1808-15.
18. Parrales A, Iwakuma T. Targeting oncogenic mutant p53 for cancer 37. Yao N, Yao D, Wang L, Dong Z, Wu W, Qiu L, Yan X, Yu D, Chen J,
therapy. Front Oncol 2015;5:288. Sai W, Zhang H, Yang J. Inhibition of autocrine IGF-II on effect of
19. Iakova P, Timchenko L, Timchenko NA. Intracellular signaling and human HepG2 cell proliferation and angiogenesis factor expression.
hepatocellular carcinoma. Semin Cancer Biol 2011;21:28-34. Tumour Biol 2012;33:1767-76.
20. Ranjan A, Bera K, Iwakuma T. Murine double minute 2, a potential 38. Mastrangelo G, Fedeli U, Fadda E, Valentini F, Agnesi R,
p53-independent regulator of liver cancer metastasis. Hepatoma Magarotto G, Marchì T, Buda A, Pinzani M, Martines D. Increased
Res 2016;2:114-21. risk of hepatocellular carcinoma and liver cirrhosis in vinyl chloride
21. Chen L, Luo L, Chen W, Xu HX, Chen F, Chen LZ, Zeng WT, Chen workers: synergistic effect of occupational exposure with alcohol
JS, Huang XH. MicroRNA-24 increases hepatocellular carcinoma intake. Environ Health Perspect 2004;112:1188-92.
cell metastasis and invasion by targeting p53: miR-24 targeted p53. 39. Dogliotti E. Molecular mechanisms of carcinogenesis by vinyl
Biomed Pharmacother 2016;84:1113-8. chloride. Ann Ist Super Sanita 2006;42:163-9.
22. Shank RC. Metabolic activation of mycotoxins by animals and 40. Dragani TA, Zocchetti C. Occupational exposure to vinyl chloride
humans: an overview. J Toxicol Environ Health 1977;2:1229-44. and risk of hepatocellular carcinoma. Cancer Causes Control
23. Hsieh DP, Atkinson DN. Bisfuranoid mycotoxins: their genotoxicity 2008;19:1193-200.
and carcinogenicity. Adv Exp Med Biol 1991;283:525-32. 41. Sherman M. Vinyl chloride and the liver. J Hepatol 2009;51:1074-
24. Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of 81.
aflatoxin-related liver cancer: systematic review and meta-analysis. 42. el Ghissassi F, Barbin A, Bartsch H. Metabolic activation of vinyl
Eur J Cancer 2012;48:2125-36. chloride by rat liver microsomes: low-dose kinetics and involvement
25. Gross-Steinmeyer K, Eaton DL. Dietary modulation of the of cytochrome P450 2E1. Biochem Pharmacol 1998;55:1445-52.
biotransformation and genotoxicity of aflatoxin B(1). Toxicology 43. Hollstein M, Marion MJ, Lehman T, Welsh J, Harris CC, Martel-
2012;299:69-79. Planche G, Kusters I, Montesano R. p53 mutations at A:T base
26. Smela ME, Currier SS, Bailey EA, Essigmann JM. The chemistry pairs in angiosarcomas of vinyl chloride-exposed factory workers.
and biology of aflatoxin B(1): from mutational spectrometry to Carcinogenesis 1994;15:1-3.
carcinogenesis. Carcinogenesis 2001;22:535-45. 44. Trivers GE, Cawley HL, DeBenedetti VM, Hollstein M, Marion
27. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations MJ, Bennett WP, Hoover ML, Prives CC, Tamburro CC, Harris
of p53 gene in hepatocellular carcinoma from southern Africa. CC. Anti-p53 antibodies in sera of workers occupationally exposed
Hepatoma Research ¦ Volume 3 ¦ June 6, 2017 101